Evidence map›Paper›PMID 41291032›Full record

ReviewThe Journal of antibiotics2026

Recent advances in lincosamide biosynthetic studies.

Yi Yang, Takahiro Mori

Abstract readReview
In one paragraph

Review in The Journal of antibiotics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Yi YangGraduate School of Pharmaceutical Sciences, The University of Tokyo, Tokyo, Japan.
Takahiro MoriGraduate School of Pharmaceutical Sciences, The University of Tokyo, Tokyo, Japan. tmori@mol.f.u-tokyo.ac.jp.ORCID http://orcid.org/0000-0002-2754-5858

Funding

MEXT | Japan Science and Technology Agency (JST) JPMJFR226IMEXT | Japan Society for the Promotion of Science (JSPS) JP23K27332MEXT | Japan Society for the Promotion of Science (JSPS) JP25H01417MEXT | Japan Society for the Promotion of Science (JSPS) JP25K22518
6 · The paper itself

Abstract

Lincomycin A and celesticetin are representative members of the lincosamide class of clinically used antibiotics produced by Streptomyces species. Their distinctive chemical architectures arise from atypical biosynthetic gene clusters that lack well observed signature genes, and since the complete determination of the lincomycin A biosynthetic pathway, current research has focused on the genetic manipulation of regulatory elements and the protein engineering of biosynthetic enzymes. This review summarizes recent advances in elucidating the transcriptional regulation of lincosamide biosynthetic gene clusters and the structure-function relationships and engineering of their biosynthetic enzymes.

Indexed as

Anti-Bacterial AgentsLincosamidesStreptomycesBiosynthetic PathwaysGene Expression Regulation, BacterialMultigene FamilyStructure-Activity RelationshipAnti-Bacterial AgentsLincosamides

Identifiers

PMID41291032
PMCPMC12945683

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.